Table 3.
Evaluation of response to MSC therapy according to the indication of MSCs.
| Days from 1st MSCs infusion to OR Median (IQR/range) | OR (n/N, %) | CR (n/N, %) | PR (n/N, %) | NR (n/N, %) | Loss of response (n/N, %) | |
|---|---|---|---|---|---|---|
| aGVHD | 15 (range 7–23) | 11/13 (84.6) | 4/11 (36.4) | 7/11 (63) | 2/13 (15.4) | 5/11 (45.5) |
| cGVHD | 21 (range 12–30) | 4/5 (80) | – | 4/4 (100) | 1/5 (20) | 1/4 (25) |
| HC | 9.5 (range 9–16) | 4/4 (100) | 2/4 (50) | 2/4 (50) | – | – |
| GF | 19.5 (range 12–27) | 2/2 (100) | 2/2 (100) | – | – | – |
| PGF | 26 (range 13–34) | 4/6 (66.7) | 3/4 (75) | 1/4 (25) | 2/6 (33.3) | – |
| All | 16 (IQR 9.75–22.25) | 25/30 (83) | 11/25 (44) | 14/25 (66) | 5/30 (17) | 6/30 (20) |
aGVHD, acute graft versus host disease; cGVHD, chronic graft versus host disease; HC, hemorrhagic cystitis; GF, graft failure; PGF, poor graft function; OR, overall response; CR, complete response; PR, partial response; NR, no response. NR, no response.